Regorafenib: from bench to bedside in colorectal cancer

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J. Clin. 62(5), 283–298 (2012).
   PubMed Web of Science ®Google Scholar
• Zauber AG, Winawer SJ, O’Brien MJ et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N. Engl. J. Med. 366(8), 687–696 (2012).
   PubMed Web of Science ®Google Scholar
• Benson AB 3rd, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 22(16), 3408–3419 (2004).
   PubMed Web of Science ®Google Scholar
• Colucci G, Gebbia V, Paoletti G et al.; Gruppo Oncologico Dell’Italia Meridionale. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J. Clin. Oncol. 23(22), 4866–4875 (2005).
   PubMed Web of Science ®Google Scholar
• Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J. Clin. Oncol. 26(21), 3523–3529 (2008).
   PubMed Web of Science ®Google Scholar
• Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J. Clin. Oncol. 19(8), 2282–2292 (2001).
   PubMed Web of Science ®Google Scholar
• Tournigand C, André T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol. 22(2), 229–237 (2004).
   PubMed Web of Science ®Google Scholar
• Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a Phase III randomised controlled trial. Lancet 370(9582), 135–142 (2007).
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O’Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 357(20), 2040–2048 (2007).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4), 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25(13), 1658–1664 (2007).
   PubMed Web of Science ®Google Scholar
• Ellis LM. Angiogenesis and its role in colorectal tumor and metastasis formation. Semin. Oncol. 31(6 Suppl. 17), 3–9 (2004).
   PubMed Web of Science ®Google Scholar
• Maeda K, Chung YS, Takatsuka S et al. Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J. Clin. Oncol. 13(2), 477–481 (1995).
   PubMed Web of Science ®Google Scholar
• Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DB. Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann. Surg. 222(6), 695–699 (1995).
   PubMed Web of Science ®Google Scholar
• Fox SH, Whalen GF, Sanders MM et al. Angiogenesis in normal tissue adjacent to colon cancer. J. Surg. Oncol. 69(4), 230–234 (1998).
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423), 841–844 (1993).
   PubMed Web of Science ®Google Scholar
• Connolly DT, Heuvelman DM, Nelson R et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 84(5), 1470–1478 (1989).
   PubMed Web of Science ®Google Scholar
• Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc. Res. 14(1), 53–65 (1977).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ et al.; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol. 25(12), 1539–1544 (2007).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann. Oncol. 20, 1842–1847 (2009).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a Phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30(28), 3499–3506 (2012).
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Dumas J, Adnane L et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129(1), 245–255 (2011).
   PubMed Web of Science ®Google Scholar
• Mross K, Frost A, Steinbild S et al. A Phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin. Cancer Res. 18(9), 2658–2667 (2012).
   PubMed Web of Science ®Google Scholar
• Shimizu T, Tolcher AW, Patnaik A et al. Phase I dose-escalation study of continuously administered regorafenib (BAY 73–4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors. J. Clin. Oncol. 28(15 Suppl.), Abstract 3035 (2010).
   Google Scholar
• Strumberg D, Scheulen ME, Schultheis B et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a Phase I study. Br. J. Cancer 106(11), 1722–1727 (2012).
   PubMed Web of Science ®Google Scholar
• Hedbom S, Steinbild S, Frost A et al. Phase I study of BAY 73–4506, a multikinase inhibitor, administered for 21 days on/7 days off in patients with advanced solid tumors. J. Clin. Oncol. 25(18 Suppl.), Abstract 3593 (2007).
   Google Scholar
• Schultheis B, Folprecht G, Kuhlmann J et al. Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second-line colorectal cancer. J Clin Oncol 29(15 Suppl.), Abstract 3585 (2011).
   Google Scholar
• Grothey A, Van Cutsem E, Sobrero A et al.; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, Phase 3 trial. Lancet 381(9863), 303–312 (2013).
   PubMed Web of Science ®Google Scholar
• Kupsch P, Henning BF, Passarge K et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin. Colorectal Cancer 5(3), 188–196 (2005).
   PubMedGoogle Scholar
• Azad N, Dasari A, Arcaroli J et al. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Invest. New Drugs 31(2), 345–354 (2013).
   PubMedGoogle Scholar
• Starling N, Vázquez-Mazón F, Cunningham D et al. A Phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Ann. Oncol. 23(1), 119–127 (2012).
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chiorean EG, Verschraegen CF et al. A Phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J. Clin. Oncol. 28(29), 4513–4520 (2010).
   PubMed Web of Science ®Google Scholar
• Qvortrup C, Jensen BV, Jorgensen TL, Nielsen D, Bjerregaard JK, Pfeiffer P. Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer. Acta Oncol. 49(6), 833–836 (2010).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Rosen LS, Marshall JL et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J. Clin. Oncol. 25(30), 4793–4799 (2007).
   PubMed Web of Science ®Google Scholar
• Sharma S, Abhyankar V, Burgess RE et al. A Phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. Ann. Oncol. 21(2), 297–304 (2010).
   PubMed Web of Science ®Google Scholar
• Gotlieb WH, Amant F, Advani S et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a Phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 13(2), 154–162 (2012).
   PubMed Web of Science ®Google Scholar
• Lockhart AC, Rothenberg ML, Dupont J et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J. Clin. Oncol. 28(2), 207–214 (2010).
   PubMed Web of Science ®Google Scholar
• Spratlin JL, Cohen RB, Eadens M et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 28(5), 780–787 (2010).
   PubMed Web of Science ®Google Scholar
• Chen E, Jonker D, Gauthier I et al. Phase I study of cediranib in combination with oxaliplatin and infusional 5-fluorouracil in patients with advanced colorectal cancer. Clin. Cancer Res. 15(4), 1481–1486 (2009).
   PubMed Web of Science ®Google Scholar
• Robertson JD, Botwood NA, Rothenberg ML, Schmoll HJ. Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. Clin. Colorectal Cancer 8(1), 59–60 (2009).
   PubMed Web of Science ®Google Scholar
• Garrett CR, Siu LL, El-Khoueiry A et al. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br. J. Cancer 105(1), 44–52 (2011).
   PubMed Web of Science ®Google Scholar
• Saunders MP, Wilson R, Peeters M et al. Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study. Cancer Chemother. Pharmacol. 64(4), 665–672 (2009).
   PubMed Web of Science ®Google Scholar
• Michael M, Gibbs P, Smith R, Godwood A, Oliver S, Tebbutt N. Open-label Phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Invest. New Drugs 27(3), 253–261 (2009).
   PubMed Web of Science ®Google Scholar
• Bouche O, Maindrault-Goebel F, Ducreux M et al. Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. Anticancer Res. 31(6), 2271–2281 (2011).
   PubMed Web of Science ®Google Scholar
• Mross K, Stefanic M, Gmehling D et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin. Cancer Res. 16(1), 311–319 (2010).
   PubMed Web of Science ®Google Scholar
• Poindessous V, Ouaret D, El Ouadrani K et al. EGFR- and VEGFR-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies. Clin. Cancer Res. 17(20), 6522–6530 (2011).
   PubMed Web of Science ®Google Scholar
• Lockhart AC, Cropp GF, Berlin JD et al. Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. Am. J. Clin. Oncol. 29(2), 109–115 (2006).
   PubMed Web of Science ®Google Scholar
• Tyagi P. Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin. Color. Cancer 5, 24–26 (2005)
   Google Scholar